Nothing Special   »   [go: up one dir, main page]

MX2016014634A - Compuestos para el tratamiento de enfermedades y trastornos oftalmicos. - Google Patents

Compuestos para el tratamiento de enfermedades y trastornos oftalmicos.

Info

Publication number
MX2016014634A
MX2016014634A MX2016014634A MX2016014634A MX2016014634A MX 2016014634 A MX2016014634 A MX 2016014634A MX 2016014634 A MX2016014634 A MX 2016014634A MX 2016014634 A MX2016014634 A MX 2016014634A MX 2016014634 A MX2016014634 A MX 2016014634A
Authority
MX
Mexico
Prior art keywords
disorders
relates
ophthalmic diseases
compounds
treating ophthalmic
Prior art date
Application number
MX2016014634A
Other languages
English (en)
Inventor
Sperl Stefan
Obermayr Franz
Original Assignee
Panoptes Pharma Ges M B H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Panoptes Pharma Ges M B H filed Critical Panoptes Pharma Ges M B H
Publication of MX2016014634A publication Critical patent/MX2016014634A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere en general al campo de productos terapéuticos oculares y el desarrollo de los mismos para uso en humanos o en animales. Más particularmente, se refiere a compuestos inhibidores de DHODH y su uso para el tratamiento de enfermedades y de trastornos oftálmicos. La invención también se refiere a la administración local de dichas composiciones oftálmicas, y en particular para su administración intravítrea. La invención también se refiere a formulaciones de liberación controlada de agentes terapéuticamente activos, en particular de compuestos inhibidores de DHODH administrados por vía intraocular, en particular en el segmento posterior del ojo.
MX2016014634A 2014-05-08 2015-05-08 Compuestos para el tratamiento de enfermedades y trastornos oftalmicos. MX2016014634A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14167490 2014-05-08
EP14170616 2014-05-30
PCT/EP2015/060166 WO2015169944A1 (en) 2014-05-08 2015-05-08 Compounds for treating ophthalmic diseases and disorders

Publications (1)

Publication Number Publication Date
MX2016014634A true MX2016014634A (es) 2017-04-10

Family

ID=53051826

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016014634A MX2016014634A (es) 2014-05-08 2015-05-08 Compuestos para el tratamiento de enfermedades y trastornos oftalmicos.

Country Status (18)

Country Link
US (2) US11730716B2 (es)
EP (1) EP3139914B1 (es)
JP (1) JP6629840B2 (es)
KR (1) KR102312186B1 (es)
CN (2) CN116077665A (es)
AU (1) AU2015257651B2 (es)
BR (1) BR112016025997A8 (es)
CA (1) CA2947067C (es)
CL (1) CL2016002812A1 (es)
ES (1) ES2960598T3 (es)
HK (1) HK1231417A1 (es)
IL (1) IL248732B (es)
MX (1) MX2016014634A (es)
NZ (1) NZ725574A (es)
PL (1) PL3139914T3 (es)
SG (1) SG11201608835VA (es)
WO (1) WO2015169944A1 (es)
ZA (1) ZA201607260B (es)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201112091D0 (en) 2011-07-14 2011-08-31 Gt Biolog Ltd Bacterial strains isolated from pigs
GB201117313D0 (en) 2011-10-07 2011-11-16 Gt Biolog Ltd Bacterium for use in medicine
GB201306536D0 (en) 2013-04-10 2013-05-22 Gt Biolog Ltd Polypeptide and immune modulation
ES2668934T3 (es) 2014-12-23 2018-05-23 4D Pharma Research Limited Polipéptido pirin y modulación inmune
JP6271093B1 (ja) 2014-12-23 2018-01-31 フォーディー ファーマ リサーチ リミテッド４Ｄ Ｐｈａｒｍａ Ｒｅｓｅａｒｃｈ Ｌｉｍｉｔｅｄ 免疫調節
PE20180267A1 (es) 2015-06-15 2018-02-06 4D Pharma Res Ltd Composiciones que comprenden cepas bacterianas
NZ777234A (en) 2015-06-15 2022-02-25 4D Pharma Res Ltd Compositions comprising bacterial strains
MA41010B1 (fr) 2015-06-15 2020-01-31 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
PE20180243A1 (es) 2015-06-15 2018-01-31 4D Pharma Res Ltd Composiciones que comprenden cepas bacterianas
MA41060B1 (fr) 2015-06-15 2019-11-29 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
ES2662617T3 (es) 2015-11-20 2018-04-09 4D Pharma Research Limited Composiciones que comprenden cepas bacterianas
GB201520497D0 (en) 2015-11-20 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201520631D0 (en) * 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201520638D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
JP6961879B2 (ja) * 2015-12-30 2021-11-05 レ ラボラトワール セルヴィエ ソシエテ・パール・アクシオンス・サンプリフィエ 変異体イソクエン酸デヒドロゲナーゼを包含する腫瘍の処置
GB201612191D0 (en) 2016-07-13 2016-08-24 4D Pharma Plc Compositions comprising bacterial strains
CN114712405A (zh) 2016-03-04 2022-07-08 4D制药有限公司 包含细菌菌株的组合物
TW201821093A (zh) 2016-07-13 2018-06-16 英商４Ｄ製藥有限公司 包含細菌菌株之組合物
GB201621123D0 (en) 2016-12-12 2017-01-25 4D Pharma Plc Compositions comprising bacterial strains
US20180369206A1 (en) 2017-04-24 2018-12-27 Aurigene Discovery Technologies Limited Methods of Use for Trisubstituted Benzotriazole Derivatives as Dihydroorotate Oxygenase Inhibitors
RS61872B1 (sr) 2017-05-22 2021-06-30 4D Pharma Res Ltd Kompozicije koje sadrže bakterijske sojeve
JP6978514B2 (ja) 2017-05-24 2021-12-08 フォーディー ファーマ リサーチ リミテッド4D Pharma Research Limited 細菌株を含む組成物
AU2018285445B2 (en) 2017-06-14 2020-03-26 Cj Bioscience, Inc. Compositions comprising bacterial strains
HUE052319T2 (hu) 2017-06-14 2021-04-28 4D Pharma Res Ltd Baktériumtörzseket tartalmazó készítmények
EP3600364B1 (en) 2017-06-14 2020-08-05 4D Pharma Research Limited Compositions comprising a bacterial strain of the genus megasphaera and uses thereof
CN110944668A (zh) 2017-06-16 2020-03-31 学校法人同志社 用于治疗或预防眼部症状、障碍或疾病的包含mTOR抑制剂的药物及其应用
JPWO2018230713A1 (ja) * 2017-06-16 2020-04-16 学校法人同志社 カスパーゼ阻害活性を有する化合物、これらの化合物を含む、角膜内皮の症状、障害または疾患を治療または予防するための医薬およびその応用
TWI818954B (zh) 2018-02-20 2023-10-21 法商施維雅藥廠 三取代之苯并三唑衍生物的使用方法
CN111163757B (zh) * 2018-03-09 2022-04-19 帕诺泰斯制药有限公司 眼用制剂
US12037305B2 (en) * 2018-03-16 2024-07-16 Immunic Ag Calcium salt polymorphs as anti-inflammatory, immunomodulatory and anti-proliferative agents
US10889548B2 (en) 2018-03-26 2021-01-12 Clear Creek Bio, Inc. Compositions and methods for inhibiting dihydroorotate dehydrogenase
US20210290651A1 (en) 2020-03-20 2021-09-23 Clear Creek Bio, Inc. Methods of treating viral infections using inhibitors of nucleotide synthesis pathways
CN116322773A (zh) * 2020-04-21 2023-06-23 马萨诸塞大学 用于治疗年龄相关性黄斑变性的方法和组合物
CN111638341A (zh) * 2020-07-01 2020-09-08 山东凯歌智能机器有限公司 一种检测小细胞肺癌患者外周血循环肿瘤细胞pd-l1基因突变的试剂盒及检测方法
JP2023545788A (ja) * 2020-10-15 2023-10-31 アスラン ファーマスーティカルズ ピーティーイー エルティーディー ジヒドロオロト酸デヒドロゲナーゼ（ｄｈｏｄｈ）阻害剤による自己免疫疾患の治療
EP4320100A1 (en) 2021-04-09 2024-02-14 Immunic AG Deuterated dhodh inhibitors
TW202332433A (zh) 2021-12-23 2023-08-16 德商埃慕尼克股份公司 含羧酸生物電子等排體之dhodh抑制劑
US20230278979A1 (en) * 2022-03-01 2023-09-07 Kiora Pharmaceuticals Gmbh Salts of a dihydroorotate dehydrogenase (dhod) inhibitor
AU2023230874A1 (en) * 2022-03-09 2024-09-19 Kiora Pharmaceuticals Gmbh Polymorphs of a dihydroorotate dehydrogenase (dhod) inhibitor

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DD297328A5 (de) * 1989-08-18 1992-01-09 �������@���������k���Kk�� 5-methyl-isoxalol-4-carbonsaeureanilide und 2 hydroxyethyliden-cyanoessigsaeureanilide zur behandlung von augenerkrankungen
AU2003301347A1 (en) * 2002-10-17 2004-05-04 Control Delivery Systems, Inc. Methods for monitoring treatment of disease
WO2004056746A1 (en) * 2002-12-23 2004-07-08 4Sc Ag Cycloalkene dicarboxylic acid compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents
EP1581478A1 (en) * 2002-12-23 2005-10-05 4Sc Ag Dhodh-inhibitors and method for their identification
CN1732147A (zh) * 2002-12-23 2006-02-08 4Sc股份公司 作为抗炎、免疫调节和抗增殖试剂的环烯二羧酸化合物
JP2006089485A (ja) * 2004-08-24 2006-04-06 Santen Pharmaceut Co Ltd ジヒドロオロテートデヒドロゲナーゼ阻害活性を有する新規複素環アミド誘導体
WO2006022442A1 (ja) * 2004-08-24 2006-03-02 Santen Pharmaceutical Co., Ltd. ジヒドロオロテートデヒドロゲナーゼ阻害活性を有する新規複素環アミド誘導体
WO2007038687A2 (en) * 2005-09-27 2007-04-05 Aciont, Inc. Ocular administration of immunosuppressive agents
ES2319596B1 (es) * 2006-12-22 2010-02-08 Laboratorios Almirall S.A. Nuevos derivados de los acidos amino-nicotinico y amino-isonicotinico.
UY31272A1 (es) 2007-08-10 2009-01-30 Almirall Lab Nuevos derivados de ácido azabifenilaminobenzoico
TWI530286B (zh) 2009-05-04 2016-04-21 帕納特斯製藥格斯有限公司 作為抑制病毒化合物之抗發炎劑
US20110021465A1 (en) * 2009-07-23 2011-01-27 U.S. Nutraceuticals, Llc D/B/A Valensa International Synergistic composition and method of retarding and ameliorating photo induced retinal damage and cataracts while ameliorating dry eye syndrome
US8686048B2 (en) 2010-05-06 2014-04-01 Rhizen Pharmaceuticals Sa Immunomodulator and anti-inflammatory compounds
CA2838289C (en) * 2011-06-10 2019-09-10 Ramscor, Inc. Sustained release formulations for delivery of proteins to the eye and methods of preparing same
AU2014390300A1 (en) * 2014-04-11 2016-10-20 Panoptes Pharma Gmbh Anti-inflammatory agents as virostatic compounds

Also Published As

Publication number Publication date
SG11201608835VA (en) 2016-11-29
KR20160147023A (ko) 2016-12-21
EP3139914C0 (en) 2023-07-26
US20230285355A1 (en) 2023-09-14
JP2017514917A (ja) 2017-06-08
US11730716B2 (en) 2023-08-22
BR112016025997A2 (pt) 2017-08-15
ES2960598T3 (es) 2024-03-05
CN116077665A (zh) 2023-05-09
KR102312186B1 (ko) 2021-10-14
AU2015257651A1 (en) 2016-11-10
CN106572968A (zh) 2017-04-19
EP3139914A1 (en) 2017-03-15
CA2947067A1 (en) 2015-11-12
ZA201607260B (en) 2018-05-30
EP3139914B1 (en) 2023-07-26
US20170071904A1 (en) 2017-03-16
HK1231417A1 (zh) 2017-12-22
WO2015169944A1 (en) 2015-11-12
JP6629840B2 (ja) 2020-01-15
IL248732B (en) 2019-07-31
CA2947067C (en) 2023-02-14
AU2015257651B2 (en) 2020-01-23
NZ725574A (en) 2022-08-26
PL3139914T3 (pl) 2023-11-27
BR112016025997A8 (pt) 2021-07-06
IL248732A0 (en) 2017-01-31
CL2016002812A1 (es) 2017-03-17

Similar Documents

Publication Publication Date Title
MX2016014634A (es) Compuestos para el tratamiento de enfermedades y trastornos oftalmicos.
MX2021009673A (es) Moduladores de ror-gamma.
TN2019000136A1 (en) 2,4,5-trisubstituted 1,2,4-triazolones useful as inhibitors of dhodh
SA518392101B1 (ar) ROR-Gamma مشتقات البنزيميدازول في صورة مُعدلات لـ
MX2019007586A (es) Composiciones que comprenden tacrolimus para el tratamiento de enfermedades inflamatorias intraoculares.
PH12016501457A1 (en) Dihydropyrrolopyridine inhibitors of ror-gamma
MX2019007587A (es) Composicion oftalmica para el tratamiento de la enfermedad del ojo seco.
MY182454A (en) Dihydropyrrolopyridine inhibitors of ror-gamma
MX2019012884A (es) Terapia de combinacion.
PH12015501942A1 (en) Susbtituted 3-phenylpropylamine derivatives for the treatment of opthalmic diseases and disorders
EA201992607A1 (ru) Твердые формы берберина урсодезоксихолата, их композиции и способы
MX360888B (es) Formulaciones oculares para suministro de fármaco al segmento posterior del ojo.
PH12017500401A1 (en) Therapeutic compounds as inhibitors of the orexin-1 receptor
MX2017005861A (es) Metodos para el control transcripcional objetivo en regiones del super mejorador.
MX2021002916A (es) Pirfenidona enriquecida con deuterio y métodos para su uso.
NZ744982A (en) Therapeutic compounds
EA202191684A1 (ru) Средство, содержащее урсодезоксихолевую кислоту, для лечения или профилактики пресбиопии
EA202191683A1 (ru) Средство, содержащее 4-фенилбутират, для профилактики или лечения пресбиопии
WO2015048188A8 (en) Modified fibroblast growth factors for the treatment of ocular disorders
MX362485B (es) Nuevos inhibidores de rock.
CL2020001426A1 (es) Composición tópica oftálmica que comprende ácido dobesilico para tratar enfermedades del segmento posterior del ojo.
PH12017501668A1 (en) Bace1 inhibitors
PH12019501820A1 (en) Pharmaceutical compositions for combination therapy
WO2017103892A3 (en) Composition for treating and preventing neurological diseases, neuroinflammation, and alzheimer's disease
MX2018006631A (es) Compuesto para uso en la prevencion y tratamiento de enfermedades neurodegenerativas.